Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This non-interventional, real-world cohort study aims to evaluate treatment patterns, clinical outcomes, and safety of BCL-2 inhibitor-based regimens in patients with CLL treated in routine clinical practice. Data collected from participating centers will be used to characterize patient demographics, disease characteristics, treatment exposure, effectiveness outcomes, and adverse events, thereby providing real-world evidence to support clinical decision-making and optimize patient management.
Trial Details
NCT Number NCT07874451
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions
(from sponsor)		 CLL / SLL
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov